Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3913]

Breast cancer incidence in post-menopausal women: Long-term influence of...

Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA

Breast cancer incidence in post-menopausal women: Long-term influence of oestrogen plus progestin versus oestrogen alone ( Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA )

Could trastuzumab deruxtecan become the new standard of care for pretreated...

Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA

Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients? ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )

Addition of S-1 to post-operative endocrine therapy for patients with hormone...

Prof Masakazu Toi - Kyoto University, Kyoto, Japan

Addition of S-1 to post-operative endocrine therapy for patients with hormone receptor-positive HER2-negative breast cancer ( Prof Masakazu Toi - Kyoto University, Kyoto, Japan )

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2...

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer...

Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1 ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML...

Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )

Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early...

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

LYRA: Maintenance therapy with daratumumab improves depth of response and...

Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA

LYRA: Maintenance therapy with daratumumab improves depth of response and achieves durable remissions in MM patients ( Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA )

KRd consolidation in MM patients with a positive PET-CT after standard first...

Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway

KRd consolidation in MM patients with a positive PET-CT after standard first-line therapy: Results from the phase II CONPET trial ( Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway )

ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with...

Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center...

ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment-naïve CLL ( Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene, USA )

More from ecancer